GT200100079A - Metodo para regular la angiogenesis utilizando proteina ryk - Google Patents

Metodo para regular la angiogenesis utilizando proteina ryk

Info

Publication number
GT200100079A
GT200100079A GT200100079A GT200100079A GT200100079A GT 200100079 A GT200100079 A GT 200100079A GT 200100079 A GT200100079 A GT 200100079A GT 200100079 A GT200100079 A GT 200100079A GT 200100079 A GT200100079 A GT 200100079A
Authority
GT
Guatemala
Prior art keywords
ryk
disease
protein
regulating angiogenesis
angiogenesis
Prior art date
Application number
GT200100079A
Other languages
English (en)
Inventor
Steve Rockzniak
Nathalie A Dubois-Stringfellow
Alya Zolotorev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200100079A publication Critical patent/GT200100079A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA INVENCION TRATA ACERCA QUE LA PROTEINA RYK QUE TIENE UNA IMPORTANTE ACTIVIDAD EN LA REGULACION DE LA ANGIOGENESIS. LA INVENCION TRATA ADEMAS DE NUEVAS PROTEINAS RYK VARIANTES QUE SON VENTAJOSAS PARA MODULAR LA ACTRIVIDAD FORMADORA DE CAPILARES DE LA CELULAS ENDOTELIALES. LAS PROTEINAS RYK VARIANTES PUEDEN SER UTILIZADAS COMO AGENTES TERAPEUTICOS EN ENFERMEDADES TALES COMO EL CANCER, LA CICATRIZACION DE HERIDAS, LAS RETINOPATIAS DIABETICAS, LA DEGENERACION MACULAR Y LAS ENFERMEDADES CARDIOVASCULARES, ASI COMO OTRAS ENFERMEDADES O TRASTORNOS CLINICOS EN LA QUE LA ANGIOGENESIS ESTA INVOLUCRADA EN LA CAUSA O EL TRATAMIENTO DE LA ENFERMEDAD.
GT200100079A 2000-05-10 2001-05-07 Metodo para regular la angiogenesis utilizando proteina ryk GT200100079A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56878300A 2000-05-10 2000-05-10

Publications (1)

Publication Number Publication Date
GT200100079A true GT200100079A (es) 2001-12-31

Family

ID=24272718

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200100079A GT200100079A (es) 2000-05-10 2001-05-07 Metodo para regular la angiogenesis utilizando proteina ryk

Country Status (13)

Country Link
EP (1) EP1287121A2 (es)
JP (1) JP2004527206A (es)
AR (1) AR028424A1 (es)
AU (1) AU2001261343A1 (es)
CA (1) CA2408349A1 (es)
CO (1) CO5300464A1 (es)
DO (1) DOP2001000164A (es)
EC (1) ECSP014068A (es)
GT (1) GT200100079A (es)
PE (1) PE20011218A1 (es)
SV (1) SV2002000442A (es)
UY (1) UY26696A1 (es)
WO (1) WO2001085789A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003066087A2 (en) * 2002-02-06 2003-08-14 Developgen Aktiengesellschaft Für Entwicklungsbiologische Forschung Kinases involved in the regulation of energy homeostasis
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
DK3170005T3 (da) 2014-07-18 2019-07-08 Sanofi Sa Fremgangsmåde til forudsigelse af resultatet af en behandling med aflibercept hos en patient, der mistænkes for at lide af cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07506969A (ja) * 1992-05-11 1995-08-03 ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ レセプタ型チロシンキナーゼ類似の分子
KR19980701950A (ko) * 1994-12-23 1998-06-25 에드워드 에이. 맥더모 2세, 로이드 제이. 오울드 분석, 리셉터 단백질 및 리간드
DE69930662T2 (de) * 1998-06-11 2006-12-28 Astrazeneca Ab Humane rezeptortyrosinkinase
ATE406907T1 (de) * 1998-10-28 2008-09-15 Cornell Res Foundation Inc Methoden zur regulierung der angiogenese und vaskuläre integrität mittels trk rezeptor liganden bdnf, nt-3 und nt-4

Also Published As

Publication number Publication date
JP2004527206A (ja) 2004-09-09
AU2001261343A1 (en) 2001-11-20
CO5300464A1 (es) 2003-07-31
SV2002000442A (es) 2002-07-03
ECSP014068A (es) 2002-02-25
AR028424A1 (es) 2003-05-07
WO2001085789A2 (en) 2001-11-15
WO2001085789A3 (en) 2002-05-16
PE20011218A1 (es) 2002-02-01
CA2408349A1 (en) 2001-11-15
EP1287121A2 (en) 2003-03-05
UY26696A1 (es) 2001-12-28
DOP2001000164A (es) 2002-05-15

Similar Documents

Publication Publication Date Title
UY28396A1 (es) Trompas de vegf y usos terapéuticos de las mismas
PL377553A1 (pl) Peptydy oraz pokrewne cząsteczki modulujące aktywność czynnika wzrostu nerwów
ES2166783T3 (es) Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii.
ATE531382T1 (de) Behandlungsmethoden von entzündungskrankheiten mit spezifisch an menschliches angiopoietin-2 bindenden wirkstoffen
ES2158115T3 (es) Derivados de histidina y homohistidina como inhibidores de la farnesiltransferasa de proteinas.
DE602004011770D1 (de) Fusionsproteine
CL2004001642A1 (es) Uso de un hidrolizado de proteina de pescado util para elaborar composiciones farmaceuticas y nutricionales, metodo de elaboracion de dicho hidrolizado.
DE60138549D1 (de) Topische gel-abgabesysteme zur behandlung von hauterkrankungen
CY1105221T1 (el) Ιατρικη χρηση θυρεοειδομιμητικων ενωσεων για την θepαπευτικη αγωγη της τριχοπτωσης και φαρμακευτικες συνθεσεις
AR039947A1 (es) Formulacion farmaceutica que comprende nicotina
CR7882A (es) Compuestos 2-(1H-Indazol-6-ilamino-benzamidas como inhibidores proteinquinasas utiles para el tratamiento de enfermedades oftalmicas
ATE554800T1 (de) Medizinische vorrichtungen mit porösen regionen zur kontrollierten aussetzung oder verabreichung therapeutischer wirkstoffe
AR030631A1 (es) Polipeptidos antiangiogenicos y metodos para inhibir la angiogenesis
ES2157422T3 (es) Trigliceridos y esteres etilicos de acido fenilalcanoico y acido fenilalquenoico utiles en el tratamiento de diversos trastornos.
DE69936381D1 (de) Verwendung von einem protein kinase hemmer wie z.b. genistein bei der behandlung von diabetischer retinopathie
ATE324105T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung von entzündungserkrankungen von kopf und nacken
ES2063370T3 (es) Agentes mejorados para el control biologico de insectos y metodos de uso.
EA200600921A1 (ru) Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
ATE205401T1 (de) Lokale behandlung von psoriasis unter verwendung neutralisierender antikörper gegen il-8
BRPI0407611A (pt) agente anti-cáncer compreendendo proteìna lk8 como um ingrediente ativo
ATE556134T1 (de) Mesenchymstammzellen und verwendungendafür
GT200100079A (es) Metodo para regular la angiogenesis utilizando proteina ryk
PT1343472E (pt) Pulverizacao nasal tixotropica
EA200401586A1 (ru) Композиции для терапевтического использования, включающие витамин а, соль металла и инсулин либо гормон роста
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.